nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—SLC22A2—Vinblastine—head and neck cancer	0.134	0.252	CbGbCtD
Imipramine—CYP2D6—Hydroxyurea—head and neck cancer	0.0948	0.179	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Docetaxel—head and neck cancer	0.0601	0.113	CbGbCtD
Imipramine—CYP3A7—Docetaxel—head and neck cancer	0.0601	0.113	CbGbCtD
Imipramine—CYP1A2—Fluorouracil—head and neck cancer	0.044	0.0829	CbGbCtD
Imipramine—ABCB1—Vinblastine—head and neck cancer	0.0356	0.0672	CbGbCtD
Imipramine—CYP2D6—Vinblastine—head and neck cancer	0.0336	0.0633	CbGbCtD
Imipramine—ABCB1—Docetaxel—head and neck cancer	0.0294	0.0554	CbGbCtD
Imipramine—CYP3A4—Vinblastine—head and neck cancer	0.0213	0.0402	CbGbCtD
Imipramine—SLC22A4—glottis—head and neck cancer	0.019	0.153	CbGeAlD
Imipramine—CYP3A4—Docetaxel—head and neck cancer	0.0176	0.0332	CbGbCtD
Imipramine—HTR7—superior cervical ganglion—head and neck cancer	0.0115	0.0929	CbGeAlD
Imipramine—Ileus paralytic—Vinblastine—head and neck cancer	0.00748	0.0317	CcSEcCtD
Imipramine—SLC22A4—larynx—head and neck cancer	0.00671	0.054	CbGeAlD
Imipramine—HRH1—nose—head and neck cancer	0.0062	0.0499	CbGeAlD
Imipramine—ORM1—saliva—head and neck cancer	0.00572	0.0461	CbGeAlD
Imipramine—Inappropriate antidiuretic hormone secretion—Vinblastine—head and neck cancer	0.00557	0.0236	CcSEcCtD
Imipramine—Skin hyperpigmentation—Hydroxyurea—head and neck cancer	0.00496	0.021	CcSEcCtD
Imipramine—HTR7—cranial nerve—head and neck cancer	0.00464	0.0374	CbGeAlD
Imipramine—Drug fever—Docetaxel—head and neck cancer	0.00459	0.0195	CcSEcCtD
Imipramine—Digestion impaired—Hydroxyurea—head and neck cancer	0.00441	0.0187	CcSEcCtD
Imipramine—Bone marrow depression—Hydroxyurea—head and neck cancer	0.00437	0.0185	CcSEcCtD
Imipramine—Sudden death—Fluorouracil—head and neck cancer	0.00415	0.0176	CcSEcCtD
Imipramine—HTR2A—trigeminal nerve—head and neck cancer	0.00406	0.0327	CbGeAlD
Imipramine—Numbness—Vinblastine—head and neck cancer	0.0039	0.0165	CcSEcCtD
Imipramine—Sinus tachycardia—Docetaxel—head and neck cancer	0.00381	0.0161	CcSEcCtD
Imipramine—Sensory loss—Vinblastine—head and neck cancer	0.00374	0.0158	CcSEcCtD
Imipramine—Skin hyperpigmentation—Fluorouracil—head and neck cancer	0.00357	0.0151	CcSEcCtD
Imipramine—HTR2A—cranial nerve—head and neck cancer	0.0029	0.0233	CbGeAlD
Imipramine—SLC22A3—tongue—head and neck cancer	0.00282	0.0227	CbGeAlD
Imipramine—Tingling sensation—Fluorouracil—head and neck cancer	0.00264	0.0112	CcSEcCtD
Imipramine—Skin hyperpigmentation—Docetaxel—head and neck cancer	0.00258	0.0109	CcSEcCtD
Imipramine—Numbness—Fluorouracil—head and neck cancer	0.00256	0.0109	CcSEcCtD
Imipramine—Speech disorder—Fluorouracil—head and neck cancer	0.00247	0.0105	CcSEcCtD
Imipramine—Sensory loss—Fluorouracil—head and neck cancer	0.00245	0.0104	CcSEcCtD
Imipramine—Cerebrovascular accident—Vinblastine—head and neck cancer	0.0024	0.0102	CcSEcCtD
Imipramine—Disorientation—Hydroxyurea—head and neck cancer	0.00239	0.0102	CcSEcCtD
Imipramine—CHRM3—exocrine gland—head and neck cancer	0.0022	0.0177	CbGeAlD
Imipramine—Dermatitis atopic—Docetaxel—head and neck cancer	0.00207	0.00878	CcSEcCtD
Imipramine—Breast disorder—Hydroxyurea—head and neck cancer	0.00194	0.00821	CcSEcCtD
Imipramine—Pancytopenia—Vinblastine—head and neck cancer	0.00193	0.00817	CcSEcCtD
Imipramine—SLC22A3—mouth—head and neck cancer	0.00189	0.0153	CbGeAlD
Imipramine—Acute coronary syndrome—Vinblastine—head and neck cancer	0.00178	0.00757	CcSEcCtD
Imipramine—SLC22A4—neck—head and neck cancer	0.00178	0.0143	CbGeAlD
Imipramine—Neuropathy peripheral—Vinblastine—head and neck cancer	0.00177	0.00752	CcSEcCtD
Imipramine—Myocardial infarction—Vinblastine—head and neck cancer	0.00177	0.00752	CcSEcCtD
Imipramine—Pancytopenia—Hydroxyurea—head and neck cancer	0.00176	0.00745	CcSEcCtD
Imipramine—Disorientation—Fluorouracil—head and neck cancer	0.00172	0.00731	CcSEcCtD
Imipramine—CHRM5—epithelium—head and neck cancer	0.00171	0.0138	CbGeAlD
Imipramine—Agranulocytosis—Vinblastine—head and neck cancer	0.00169	0.00716	CcSEcCtD
Imipramine—Weight increased—Hydroxyurea—head and neck cancer	0.00168	0.00714	CcSEcCtD
Imipramine—Infestation—Hydroxyurea—head and neck cancer	0.00165	0.007	CcSEcCtD
Imipramine—Infestation NOS—Hydroxyurea—head and neck cancer	0.00165	0.007	CcSEcCtD
Imipramine—Drowsiness—Hydroxyurea—head and neck cancer	0.00165	0.007	CcSEcCtD
Imipramine—KCND2—head—head and neck cancer	0.00163	0.0132	CbGeAlD
Imipramine—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.00162	0.00686	CcSEcCtD
Imipramine—Hypoaesthesia—Vinblastine—head and neck cancer	0.00162	0.00685	CcSEcCtD
Imipramine—Stomatitis—Hydroxyurea—head and neck cancer	0.00161	0.00682	CcSEcCtD
Imipramine—KCND3—thyroid gland—head and neck cancer	0.00161	0.0129	CbGeAlD
Imipramine—Cardiac failure—Fluorouracil—head and neck cancer	0.00158	0.0067	CcSEcCtD
Imipramine—HTR7—mouth—head and neck cancer	0.00156	0.0126	CbGeAlD
Imipramine—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.00156	0.00662	CcSEcCtD
Imipramine—Blood pressure increased—Docetaxel—head and neck cancer	0.00153	0.0065	CcSEcCtD
Imipramine—ADRA1D—epithelium—head and neck cancer	0.00153	0.0123	CbGeAlD
Imipramine—Hallucination—Hydroxyurea—head and neck cancer	0.00147	0.00625	CcSEcCtD
Imipramine—Ataxia—Fluorouracil—head and neck cancer	0.00145	0.00615	CcSEcCtD
Imipramine—Alopecia—Vinblastine—head and neck cancer	0.00144	0.00609	CcSEcCtD
Imipramine—KCND3—head—head and neck cancer	0.00142	0.0115	CbGeAlD
Imipramine—CHRM4—head—head and neck cancer	0.00136	0.0109	CbGeAlD
Imipramine—Angiopathy—Hydroxyurea—head and neck cancer	0.00134	0.0057	CcSEcCtD
Imipramine—HTR7—neck—head and neck cancer	0.00134	0.0108	CbGeAlD
Imipramine—Eosinophilia—Fluorouracil—head and neck cancer	0.00132	0.00559	CcSEcCtD
Imipramine—SLC22A3—parotid gland—head and neck cancer	0.00132	0.0106	CbGeAlD
Imipramine—Ill-defined disorder—Vinblastine—head and neck cancer	0.00131	0.00556	CcSEcCtD
Imipramine—Alopecia—Hydroxyurea—head and neck cancer	0.00131	0.00555	CcSEcCtD
Imipramine—CHRM1—parotid gland—head and neck cancer	0.00128	0.0103	CbGeAlD
Imipramine—Malaise—Vinblastine—head and neck cancer	0.00128	0.00541	CcSEcCtD
Imipramine—Leukopenia—Vinblastine—head and neck cancer	0.00127	0.00537	CcSEcCtD
Imipramine—Pancytopenia—Fluorouracil—head and neck cancer	0.00127	0.00537	CcSEcCtD
Imipramine—SLC22A3—saliva-secreting gland—head and neck cancer	0.00126	0.0102	CbGeAlD
Imipramine—Cardiac failure congestive—Docetaxel—head and neck cancer	0.00123	0.0052	CcSEcCtD
Imipramine—Convulsion—Vinblastine—head and neck cancer	0.00123	0.0052	CcSEcCtD
Imipramine—CHRM1—saliva-secreting gland—head and neck cancer	0.00122	0.00986	CbGeAlD
Imipramine—Hypertension—Vinblastine—head and neck cancer	0.00122	0.00518	CcSEcCtD
Imipramine—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.00122	0.00516	CcSEcCtD
Imipramine—HTR6—head—head and neck cancer	0.00121	0.00978	CbGeAlD
Imipramine—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.0012	0.00507	CcSEcCtD
Imipramine—Discomfort—Vinblastine—head and neck cancer	0.00119	0.00504	CcSEcCtD
Imipramine—Hot flush—Docetaxel—head and neck cancer	0.00119	0.00504	CcSEcCtD
Imipramine—Infestation—Fluorouracil—head and neck cancer	0.00119	0.00504	CcSEcCtD
Imipramine—Infestation NOS—Fluorouracil—head and neck cancer	0.00119	0.00504	CcSEcCtD
Imipramine—Menopausal symptoms—Docetaxel—head and neck cancer	0.00118	0.005	CcSEcCtD
Imipramine—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.00117	0.00497	CcSEcCtD
Imipramine—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.00116	0.00494	CcSEcCtD
Imipramine—Myocardial infarction—Fluorouracil—head and neck cancer	0.00116	0.00494	CcSEcCtD
Imipramine—Malaise—Hydroxyurea—head and neck cancer	0.00116	0.00493	CcSEcCtD
Imipramine—SLC22A3—connective tissue—head and neck cancer	0.00116	0.00935	CbGeAlD
Imipramine—Stomatitis—Fluorouracil—head and neck cancer	0.00116	0.00491	CcSEcCtD
Imipramine—Leukopenia—Hydroxyurea—head and neck cancer	0.00115	0.0049	CcSEcCtD
Imipramine—Cardiac failure—Docetaxel—head and neck cancer	0.00114	0.00483	CcSEcCtD
Imipramine—Thrombocytopenia—Vinblastine—head and neck cancer	0.00113	0.00479	CcSEcCtD
Imipramine—Convulsion—Hydroxyurea—head and neck cancer	0.00112	0.00474	CcSEcCtD
Imipramine—Agranulocytosis—Fluorouracil—head and neck cancer	0.00111	0.0047	CcSEcCtD
Imipramine—Anorexia—Vinblastine—head and neck cancer	0.0011	0.00467	CcSEcCtD
Imipramine—CHRM3—saliva-secreting gland—head and neck cancer	0.0011	0.00882	CbGeAlD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00109	0.00462	CcSEcCtD
Imipramine—Discomfort—Hydroxyurea—head and neck cancer	0.00109	0.0046	CcSEcCtD
Imipramine—SLC22A4—trachea—head and neck cancer	0.00107	0.00862	CbGeAlD
Imipramine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00106	0.0045	CcSEcCtD
Imipramine—CHRM5—head—head and neck cancer	0.00106	0.00854	CbGeAlD
Imipramine—Oedema—Hydroxyurea—head and neck cancer	0.00105	0.00446	CcSEcCtD
Imipramine—Ataxia—Docetaxel—head and neck cancer	0.00105	0.00444	CcSEcCtD
Imipramine—Infection—Hydroxyurea—head and neck cancer	0.00105	0.00443	CcSEcCtD
Imipramine—Paraesthesia—Vinblastine—head and neck cancer	0.00104	0.0044	CcSEcCtD
Imipramine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00103	0.00438	CcSEcCtD
Imipramine—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00103	0.00437	CcSEcCtD
Imipramine—Liver function test abnormal—Docetaxel—head and neck cancer	0.00103	0.00436	CcSEcCtD
Imipramine—Skin disorder—Hydroxyurea—head and neck cancer	0.00102	0.00434	CcSEcCtD
Imipramine—Orthostatic hypotension—Docetaxel—head and neck cancer	0.00102	0.00431	CcSEcCtD
Imipramine—Breast disorder—Docetaxel—head and neck cancer	0.00101	0.00426	CcSEcCtD
Imipramine—Anorexia—Hydroxyurea—head and neck cancer	0.001	0.00425	CcSEcCtD
Imipramine—Decreased appetite—Vinblastine—head and neck cancer	0.001	0.00425	CcSEcCtD
Imipramine—KCND3—lymph node—head and neck cancer	0.000998	0.00804	CbGeAlD
Imipramine—Constipation—Vinblastine—head and neck cancer	0.000987	0.00419	CcSEcCtD
Imipramine—ADRA1B—head—head and neck cancer	0.000969	0.00781	CbGeAlD
Imipramine—HTR7—connective tissue—head and neck cancer	0.000958	0.00772	CbGeAlD
Imipramine—Arrhythmia—Fluorouracil—head and neck cancer	0.000953	0.00404	CcSEcCtD
Imipramine—Feeling abnormal—Vinblastine—head and neck cancer	0.000951	0.00403	CcSEcCtD
Imipramine—ADRA1D—head—head and neck cancer	0.000948	0.00764	CbGeAlD
Imipramine—CHRM1—trachea—head and neck cancer	0.000944	0.00761	CbGeAlD
Imipramine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000944	0.004	CcSEcCtD
Imipramine—Alopecia—Fluorouracil—head and neck cancer	0.000943	0.004	CcSEcCtD
Imipramine—Somnolence—Hydroxyurea—head and neck cancer	0.000936	0.00397	CcSEcCtD
Imipramine—Dyspepsia—Hydroxyurea—head and neck cancer	0.000927	0.00393	CcSEcCtD
Imipramine—Decreased appetite—Hydroxyurea—head and neck cancer	0.000915	0.00388	CcSEcCtD
Imipramine—Pancytopenia—Docetaxel—head and neck cancer	0.000913	0.00387	CcSEcCtD
Imipramine—Abdominal pain—Vinblastine—head and neck cancer	0.000913	0.00387	CcSEcCtD
Imipramine—HTR7—epithelium—head and neck cancer	0.00091	0.00733	CbGeAlD
Imipramine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000909	0.00385	CcSEcCtD
Imipramine—Fatigue—Hydroxyurea—head and neck cancer	0.000908	0.00385	CcSEcCtD
Imipramine—Constipation—Hydroxyurea—head and neck cancer	0.0009	0.00382	CcSEcCtD
Imipramine—ADRA1A—epithelium—head and neck cancer	0.000877	0.00707	CbGeAlD
Imipramine—Weight increased—Docetaxel—head and neck cancer	0.000875	0.00371	CcSEcCtD
Imipramine—Vision blurred—Fluorouracil—head and neck cancer	0.000875	0.00371	CcSEcCtD
Imipramine—Weight decreased—Docetaxel—head and neck cancer	0.00087	0.00369	CcSEcCtD
Imipramine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.000868	0.00368	CcSEcCtD
Imipramine—Infestation—Docetaxel—head and neck cancer	0.000858	0.00364	CcSEcCtD
Imipramine—Infestation NOS—Docetaxel—head and neck cancer	0.000858	0.00364	CcSEcCtD
Imipramine—SLC22A4—thyroid gland—head and neck cancer	0.000847	0.00682	CbGeAlD
Imipramine—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000845	0.00358	CcSEcCtD
Imipramine—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000841	0.00356	CcSEcCtD
Imipramine—Myocardial infarction—Docetaxel—head and neck cancer	0.000841	0.00356	CcSEcCtD
Imipramine—Jaundice—Docetaxel—head and neck cancer	0.000836	0.00354	CcSEcCtD
Imipramine—Stomatitis—Docetaxel—head and neck cancer	0.000836	0.00354	CcSEcCtD
Imipramine—HTR2A—neck—head and neck cancer	0.000834	0.00672	CbGeAlD
Imipramine—Body temperature increased—Hydroxyurea—head and neck cancer	0.000832	0.00353	CcSEcCtD
Imipramine—Leukopenia—Fluorouracil—head and neck cancer	0.000831	0.00352	CcSEcCtD
Imipramine—Asthenia—Vinblastine—head and neck cancer	0.000828	0.00351	CcSEcCtD
Imipramine—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000811	0.00344	CcSEcCtD
Imipramine—Convulsion—Fluorouracil—head and neck cancer	0.000804	0.00341	CcSEcCtD
Imipramine—HTR7—trachea—head and neck cancer	0.000804	0.00648	CbGeAlD
Imipramine—Agranulocytosis—Docetaxel—head and neck cancer	0.0008	0.00339	CcSEcCtD
Imipramine—Diarrhoea—Vinblastine—head and neck cancer	0.00079	0.00335	CcSEcCtD
Imipramine—Discomfort—Fluorouracil—head and neck cancer	0.000781	0.00331	CcSEcCtD
Imipramine—SLC22A3—thyroid gland—head and neck cancer	0.000771	0.00621	CbGeAlD
Imipramine—Hepatitis—Docetaxel—head and neck cancer	0.00077	0.00326	CcSEcCtD
Imipramine—Hypoaesthesia—Docetaxel—head and neck cancer	0.000766	0.00325	CcSEcCtD
Imipramine—Confusional state—Fluorouracil—head and neck cancer	0.000764	0.00324	CcSEcCtD
Imipramine—Dizziness—Vinblastine—head and neck cancer	0.000763	0.00324	CcSEcCtD
Imipramine—Urinary tract disorder—Docetaxel—head and neck cancer	0.00076	0.00322	CcSEcCtD
Imipramine—Anaphylactic shock—Fluorouracil—head and neck cancer	0.000758	0.00321	CcSEcCtD
Imipramine—Oedema—Fluorouracil—head and neck cancer	0.000758	0.00321	CcSEcCtD
Imipramine—Asthenia—Hydroxyurea—head and neck cancer	0.000755	0.0032	CcSEcCtD
Imipramine—Urethral disorder—Docetaxel—head and neck cancer	0.000755	0.0032	CcSEcCtD
Imipramine—Infection—Fluorouracil—head and neck cancer	0.000753	0.00319	CcSEcCtD
Imipramine—Nervous system disorder—Fluorouracil—head and neck cancer	0.000743	0.00315	CcSEcCtD
Imipramine—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000742	0.00315	CcSEcCtD
Imipramine—Tachycardia—Fluorouracil—head and neck cancer	0.00074	0.00314	CcSEcCtD
Imipramine—Vomiting—Vinblastine—head and neck cancer	0.000734	0.00311	CcSEcCtD
Imipramine—CHRM2—head—head and neck cancer	0.000728	0.00587	CbGeAlD
Imipramine—SLC6A3—head—head and neck cancer	0.000726	0.00585	CbGeAlD
Imipramine—Headache—Vinblastine—head and neck cancer	0.000723	0.00307	CcSEcCtD
Imipramine—Anorexia—Fluorouracil—head and neck cancer	0.000722	0.00306	CcSEcCtD
Imipramine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00072	0.00305	CcSEcCtD
Imipramine—Eye disorder—Docetaxel—head and neck cancer	0.000719	0.00305	CcSEcCtD
Imipramine—HRH1—connective tissue—head and neck cancer	0.000715	0.00576	CbGeAlD
Imipramine—SLC22A1—head—head and neck cancer	0.000715	0.00576	CbGeAlD
Imipramine—Cardiac disorder—Docetaxel—head and neck cancer	0.000714	0.00303	CcSEcCtD
Imipramine—Flushing—Docetaxel—head and neck cancer	0.000714	0.00303	CcSEcCtD
Imipramine—HTR2C—head—head and neck cancer	0.000702	0.00565	CbGeAlD
Imipramine—Angiopathy—Docetaxel—head and neck cancer	0.000698	0.00296	CcSEcCtD
Imipramine—Dizziness—Hydroxyurea—head and neck cancer	0.000696	0.00295	CcSEcCtD
Imipramine—Immune system disorder—Docetaxel—head and neck cancer	0.000695	0.00295	CcSEcCtD
Imipramine—Mediastinal disorder—Docetaxel—head and neck cancer	0.000694	0.00294	CcSEcCtD
Imipramine—Arrhythmia—Docetaxel—head and neck cancer	0.000688	0.00292	CcSEcCtD
Imipramine—Nausea—Vinblastine—head and neck cancer	0.000686	0.00291	CcSEcCtD
Imipramine—Insomnia—Fluorouracil—head and neck cancer	0.000685	0.00291	CcSEcCtD
Imipramine—SLC22A3—head—head and neck cancer	0.000684	0.00551	CbGeAlD
Imipramine—Paraesthesia—Fluorouracil—head and neck cancer	0.00068	0.00289	CcSEcCtD
Imipramine—Alopecia—Docetaxel—head and neck cancer	0.00068	0.00288	CcSEcCtD
Imipramine—HRH1—epithelium—head and neck cancer	0.000679	0.00547	CbGeAlD
Imipramine—ADRA1A—lymphoid tissue—head and neck cancer	0.000676	0.00544	CbGeAlD
Imipramine—Mental disorder—Docetaxel—head and neck cancer	0.000674	0.00286	CcSEcCtD
Imipramine—Somnolence—Fluorouracil—head and neck cancer	0.000674	0.00286	CcSEcCtD
Imipramine—Malnutrition—Docetaxel—head and neck cancer	0.00067	0.00284	CcSEcCtD
Imipramine—Vomiting—Hydroxyurea—head and neck cancer	0.000669	0.00284	CcSEcCtD
Imipramine—CHRM3—thyroid gland—head and neck cancer	0.000669	0.00539	CbGeAlD
Imipramine—Dyspepsia—Fluorouracil—head and neck cancer	0.000667	0.00283	CcSEcCtD
Imipramine—SLC6A4—head—head and neck cancer	0.000665	0.00536	CbGeAlD
Imipramine—Rash—Hydroxyurea—head and neck cancer	0.000664	0.00281	CcSEcCtD
Imipramine—Dermatitis—Hydroxyurea—head and neck cancer	0.000663	0.00281	CcSEcCtD
Imipramine—CHRM1—head—head and neck cancer	0.000663	0.00534	CbGeAlD
Imipramine—Headache—Hydroxyurea—head and neck cancer	0.00066	0.0028	CcSEcCtD
Imipramine—Decreased appetite—Fluorouracil—head and neck cancer	0.000659	0.00279	CcSEcCtD
Imipramine—Dysgeusia—Docetaxel—head and neck cancer	0.000656	0.00278	CcSEcCtD
Imipramine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000654	0.00277	CcSEcCtD
Imipramine—Nausea—Hydroxyurea—head and neck cancer	0.000625	0.00265	CcSEcCtD
Imipramine—Feeling abnormal—Fluorouracil—head and neck cancer	0.000624	0.00265	CcSEcCtD
Imipramine—Urticaria—Fluorouracil—head and neck cancer	0.000602	0.00255	CcSEcCtD
Imipramine—Syncope—Docetaxel—head and neck cancer	0.000601	0.00255	CcSEcCtD
Imipramine—HRH1—trachea—head and neck cancer	0.000601	0.00484	CbGeAlD
Imipramine—Leukopenia—Docetaxel—head and neck cancer	0.0006	0.00254	CcSEcCtD
Imipramine—Body temperature increased—Fluorouracil—head and neck cancer	0.000599	0.00254	CcSEcCtD
Imipramine—HTR2A—connective tissue—head and neck cancer	0.000598	0.00481	CbGeAlD
Imipramine—CHRM3—head—head and neck cancer	0.000593	0.00478	CbGeAlD
Imipramine—Palpitations—Docetaxel—head and neck cancer	0.000592	0.00251	CcSEcCtD
Imipramine—HTR1A—head—head and neck cancer	0.000591	0.00476	CbGeAlD
Imipramine—Loss of consciousness—Docetaxel—head and neck cancer	0.000589	0.0025	CcSEcCtD
Imipramine—SLC6A2—head—head and neck cancer	0.000586	0.00472	CbGeAlD
Imipramine—Convulsion—Docetaxel—head and neck cancer	0.000581	0.00246	CcSEcCtD
Imipramine—Hypertension—Docetaxel—head and neck cancer	0.000579	0.00245	CcSEcCtD
Imipramine—HTR2A—epithelium—head and neck cancer	0.000567	0.00457	CbGeAlD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000567	0.0024	CcSEcCtD
Imipramine—HTR7—head—head and neck cancer	0.000565	0.00455	CbGeAlD
Imipramine—Dry mouth—Docetaxel—head and neck cancer	0.000558	0.00237	CcSEcCtD
Imipramine—Confusional state—Docetaxel—head and neck cancer	0.000551	0.00234	CcSEcCtD
Imipramine—Oedema—Docetaxel—head and neck cancer	0.000547	0.00232	CcSEcCtD
Imipramine—Anaphylactic shock—Docetaxel—head and neck cancer	0.000547	0.00232	CcSEcCtD
Imipramine—ORM1—lymph node—head and neck cancer	0.000547	0.0044	CbGeAlD
Imipramine—ADRA1A—head—head and neck cancer	0.000545	0.00439	CbGeAlD
Imipramine—Infection—Docetaxel—head and neck cancer	0.000543	0.0023	CcSEcCtD
Imipramine—Shock—Docetaxel—head and neck cancer	0.000538	0.00228	CcSEcCtD
Imipramine—Nervous system disorder—Docetaxel—head and neck cancer	0.000536	0.00227	CcSEcCtD
Imipramine—Pruritus—Fluorouracil—head and neck cancer	0.000536	0.00227	CcSEcCtD
Imipramine—CYP2B6—lymphoid tissue—head and neck cancer	0.000536	0.00431	CbGeAlD
Imipramine—Thrombocytopenia—Docetaxel—head and neck cancer	0.000536	0.00227	CcSEcCtD
Imipramine—Tachycardia—Docetaxel—head and neck cancer	0.000534	0.00226	CcSEcCtD
Imipramine—DRD2—head—head and neck cancer	0.000534	0.0043	CbGeAlD
Imipramine—Skin disorder—Docetaxel—head and neck cancer	0.000531	0.00225	CcSEcCtD
Imipramine—SLC22A4—lymph node—head and neck cancer	0.000526	0.00424	CbGeAlD
Imipramine—KCNH2—head—head and neck cancer	0.000526	0.00424	CbGeAlD
Imipramine—Anorexia—Docetaxel—head and neck cancer	0.000521	0.00221	CcSEcCtD
Imipramine—Diarrhoea—Fluorouracil—head and neck cancer	0.000518	0.0022	CcSEcCtD
Imipramine—CYP1A2—thyroid gland—head and neck cancer	0.000508	0.00409	CbGeAlD
Imipramine—CYP2E1—lymphoid tissue—head and neck cancer	0.000503	0.00405	CbGeAlD
Imipramine—HTR2A—trachea—head and neck cancer	0.000502	0.00404	CbGeAlD
Imipramine—Dizziness—Fluorouracil—head and neck cancer	0.000501	0.00212	CcSEcCtD
Imipramine—Insomnia—Docetaxel—head and neck cancer	0.000495	0.0021	CcSEcCtD
Imipramine—Paraesthesia—Docetaxel—head and neck cancer	0.000491	0.00208	CcSEcCtD
Imipramine—Somnolence—Docetaxel—head and neck cancer	0.000486	0.00206	CcSEcCtD
Imipramine—Vomiting—Fluorouracil—head and neck cancer	0.000482	0.00204	CcSEcCtD
Imipramine—Dyspepsia—Docetaxel—head and neck cancer	0.000481	0.00204	CcSEcCtD
Imipramine—SLC22A3—lymph node—head and neck cancer	0.000479	0.00386	CbGeAlD
Imipramine—Rash—Fluorouracil—head and neck cancer	0.000478	0.00203	CcSEcCtD
Imipramine—Dermatitis—Fluorouracil—head and neck cancer	0.000477	0.00202	CcSEcCtD
Imipramine—Decreased appetite—Docetaxel—head and neck cancer	0.000475	0.00202	CcSEcCtD
Imipramine—Headache—Fluorouracil—head and neck cancer	0.000475	0.00201	CcSEcCtD
Imipramine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000472	0.002	CcSEcCtD
Imipramine—Fatigue—Docetaxel—head and neck cancer	0.000472	0.002	CcSEcCtD
Imipramine—Constipation—Docetaxel—head and neck cancer	0.000468	0.00198	CcSEcCtD
Imipramine—CYP2E1—thyroid gland—head and neck cancer	0.000457	0.00368	CbGeAlD
Imipramine—Feeling abnormal—Docetaxel—head and neck cancer	0.000451	0.00191	CcSEcCtD
Imipramine—Nausea—Fluorouracil—head and neck cancer	0.00045	0.00191	CcSEcCtD
Imipramine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000447	0.0019	CcSEcCtD
Imipramine—Body temperature increased—Docetaxel—head and neck cancer	0.000432	0.00183	CcSEcCtD
Imipramine—Abdominal pain—Docetaxel—head and neck cancer	0.000432	0.00183	CcSEcCtD
Imipramine—CYP2B6—head—head and neck cancer	0.000432	0.00348	CbGeAlD
Imipramine—HRH1—head—head and neck cancer	0.000422	0.0034	CbGeAlD
Imipramine—SLC6A2—lymph node—head and neck cancer	0.00041	0.0033	CbGeAlD
Imipramine—CYP2E1—head—head and neck cancer	0.000405	0.00326	CbGeAlD
Imipramine—Asthenia—Docetaxel—head and neck cancer	0.000392	0.00166	CcSEcCtD
Imipramine—Pruritus—Docetaxel—head and neck cancer	0.000387	0.00164	CcSEcCtD
Imipramine—Diarrhoea—Docetaxel—head and neck cancer	0.000374	0.00159	CcSEcCtD
Imipramine—ABCB1—epithelium—head and neck cancer	0.000372	0.00299	CbGeAlD
Imipramine—KCNH2—lymph node—head and neck cancer	0.000368	0.00297	CbGeAlD
Imipramine—Dizziness—Docetaxel—head and neck cancer	0.000362	0.00153	CcSEcCtD
Imipramine—HTR2A—head—head and neck cancer	0.000352	0.00284	CbGeAlD
Imipramine—Vomiting—Docetaxel—head and neck cancer	0.000348	0.00147	CcSEcCtD
Imipramine—Rash—Docetaxel—head and neck cancer	0.000345	0.00146	CcSEcCtD
Imipramine—Dermatitis—Docetaxel—head and neck cancer	0.000345	0.00146	CcSEcCtD
Imipramine—Headache—Docetaxel—head and neck cancer	0.000343	0.00145	CcSEcCtD
Imipramine—ABCB1—trachea—head and neck cancer	0.000329	0.00265	CbGeAlD
Imipramine—Nausea—Docetaxel—head and neck cancer	0.000325	0.00138	CcSEcCtD
Imipramine—CYP2D6—head—head and neck cancer	0.000321	0.00258	CbGeAlD
Imipramine—HRH1—lymph node—head and neck cancer	0.000295	0.00238	CbGeAlD
Imipramine—ABCB1—lymphoid tissue—head and neck cancer	0.000286	0.00231	CbGeAlD
Imipramine—ABCB1—thyroid gland—head and neck cancer	0.00026	0.00209	CbGeAlD
Imipramine—ABCB1—head—head and neck cancer	0.000231	0.00186	CbGeAlD
Imipramine—ABCB1—lymph node—head and neck cancer	0.000162	0.0013	CbGeAlD
Imipramine—HRH1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.32e-05	0.000121	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—PIK3CA—head and neck cancer	1.32e-05	0.00012	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—PIK3CA—head and neck cancer	1.31e-05	0.00012	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—AKT1—head and neck cancer	1.3e-05	0.000119	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—PIK3CA—head and neck cancer	1.3e-05	0.000119	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.3e-05	0.000118	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PTEN—head and neck cancer	1.29e-05	0.000118	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—HRAS—head and neck cancer	1.29e-05	0.000118	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—VEGFA—head and neck cancer	1.28e-05	0.000117	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	1.28e-05	0.000117	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—MAPK1—head and neck cancer	1.28e-05	0.000117	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—EGFR—head and neck cancer	1.28e-05	0.000117	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—MAPK1—head and neck cancer	1.28e-05	0.000117	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—EGFR—head and neck cancer	1.28e-05	0.000117	CbGpPWpGaD
Imipramine—SLC22A3—Metabolism—AKT1—head and neck cancer	1.27e-05	0.000116	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—STAT3—head and neck cancer	1.27e-05	0.000116	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MAPK3—head and neck cancer	1.27e-05	0.000116	CbGpPWpGaD
Imipramine—HTR1A—GPCR downstream signaling—AKT1—head and neck cancer	1.25e-05	0.000114	CbGpPWpGaD
Imipramine—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	1.25e-05	0.000114	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—TYMS—head and neck cancer	1.24e-05	0.000114	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL2—head and neck cancer	1.24e-05	0.000113	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL2—head and neck cancer	1.23e-05	0.000112	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GSTM1—head and neck cancer	1.23e-05	0.000112	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.23e-05	0.000112	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—HRAS—head and neck cancer	1.23e-05	0.000112	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—PIK3CA—head and neck cancer	1.22e-05	0.000112	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MAPK3—head and neck cancer	1.22e-05	0.000111	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—VEGFA—head and neck cancer	1.21e-05	0.00011	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CCND1—head and neck cancer	1.21e-05	0.00011	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MAPK1—head and neck cancer	1.21e-05	0.00011	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—EGFR—head and neck cancer	1.21e-05	0.00011	CbGpPWpGaD
Imipramine—CYP2C18—Metabolism—AKT1—head and neck cancer	1.2e-05	0.00011	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.2e-05	0.00011	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CCND1—head and neck cancer	1.2e-05	0.00011	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—PIK3CA—head and neck cancer	1.2e-05	0.00011	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—STAT3—head and neck cancer	1.2e-05	0.000109	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—PIK3CA—head and neck cancer	1.2e-05	0.000109	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PTEN—head and neck cancer	1.19e-05	0.000109	CbGpPWpGaD
Imipramine—ADRA1B—GPCR downstream signaling—AKT1—head and neck cancer	1.19e-05	0.000109	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—PIK3CA—head and neck cancer	1.19e-05	0.000109	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—PIK3CA—head and neck cancer	1.18e-05	0.000108	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL2—head and neck cancer	1.18e-05	0.000108	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—GPX1—head and neck cancer	1.18e-05	0.000108	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTGS2—head and neck cancer	1.18e-05	0.000108	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—PIK3CA—head and neck cancer	1.18e-05	0.000107	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—CYP1A1—head and neck cancer	1.17e-05	0.000106	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PTEN—head and neck cancer	1.17e-05	0.000106	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.16e-05	0.000106	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MAPK1—head and neck cancer	1.16e-05	0.000106	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—EGFR—head and neck cancer	1.16e-05	0.000106	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTGS2—head and neck cancer	1.15e-05	0.000105	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CCND1—head and neck cancer	1.15e-05	0.000105	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MAPK3—head and neck cancer	1.14e-05	0.000104	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—AKT1—head and neck cancer	1.14e-05	0.000104	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.13e-05	0.000103	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—HRAS—head and neck cancer	1.13e-05	0.000103	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.11e-05	0.000102	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—PIK3CA—head and neck cancer	1.11e-05	0.000101	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—HRAS—head and neck cancer	1.11e-05	0.000101	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PTEN—head and neck cancer	1.11e-05	0.000101	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—PIK3CA—head and neck cancer	1.11e-05	0.000101	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—HRAS—head and neck cancer	1.11e-05	0.000101	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—HRAS—head and neck cancer	1.1e-05	0.000101	CbGpPWpGaD
Imipramine—DRD2—GPCR downstream signaling—AKT1—head and neck cancer	1.1e-05	0.0001	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—HRAS—head and neck cancer	1.09e-05	9.97e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—HRAS—head and neck cancer	1.09e-05	9.94e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL2—head and neck cancer	1.09e-05	9.93e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MAPK1—head and neck cancer	1.09e-05	9.92e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—EGFR—head and neck cancer	1.09e-05	9.92e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—AKT1—head and neck cancer	1.08e-05	9.88e-05	CbGpPWpGaD
Imipramine—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.08e-05	9.87e-05	CbGpPWpGaD
Imipramine—HRH1—GPCR downstream signaling—AKT1—head and neck cancer	1.08e-05	9.85e-05	CbGpPWpGaD
Imipramine—CHRM1—GPCR downstream signaling—AKT1—head and neck cancer	1.08e-05	9.82e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—head and neck cancer	1.07e-05	9.81e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—head and neck cancer	1.07e-05	9.8e-05	CbGpPWpGaD
Imipramine—CHRM3—GPCR downstream signaling—AKT1—head and neck cancer	1.07e-05	9.79e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.07e-05	9.77e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL2—head and neck cancer	1.07e-05	9.75e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL2—head and neck cancer	1.06e-05	9.72e-05	CbGpPWpGaD
Imipramine—CHRM2—GPCR downstream signaling—AKT1—head and neck cancer	1.06e-05	9.69e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL2—head and neck cancer	1.06e-05	9.69e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CCND1—head and neck cancer	1.06e-05	9.68e-05	CbGpPWpGaD
Imipramine—ADRA1A—GPCR downstream signaling—AKT1—head and neck cancer	1.06e-05	9.67e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—VEGFA—head and neck cancer	1.05e-05	9.61e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL2—head and neck cancer	1.05e-05	9.59e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL2—head and neck cancer	1.05e-05	9.56e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—PIK3CA—head and neck cancer	1.05e-05	9.56e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.05e-05	9.56e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.04e-05	9.52e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—STAT3—head and neck cancer	1.04e-05	9.51e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CCND1—head and neck cancer	1.04e-05	9.5e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CCND1—head and neck cancer	1.04e-05	9.47e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.04e-05	9.47e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CCND1—head and neck cancer	1.03e-05	9.44e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—head and neck cancer	1.03e-05	9.38e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PTEN—head and neck cancer	1.03e-05	9.38e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—head and neck cancer	1.03e-05	9.37e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—head and neck cancer	1.02e-05	9.35e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PTEN—head and neck cancer	1.02e-05	9.34e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—head and neck cancer	1.02e-05	9.32e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—head and neck cancer	1.01e-05	9.25e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.01e-05	9.19e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PTEN—head and neck cancer	1.01e-05	9.18e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PTEN—head and neck cancer	1e-05	9.17e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—PIK3CA—head and neck cancer	1e-05	9.16e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—head and neck cancer	1e-05	9.15e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PTEN—head and neck cancer	1e-05	9.14e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—AKT1—head and neck cancer	9.98e-06	9.11e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PTEN—head and neck cancer	9.98e-06	9.11e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MAPK3—head and neck cancer	9.96e-06	9.09e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—STAT3—head and neck cancer	9.93e-06	9.06e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	9.91e-06	9.04e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PTEN—head and neck cancer	9.89e-06	9.02e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PTEN—head and neck cancer	9.86e-06	9e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	9.82e-06	8.97e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—AKT1—head and neck cancer	9.8e-06	8.95e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—PIK3CA—head and neck cancer	9.8e-06	8.94e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—PIK3CA—head and neck cancer	9.78e-06	8.93e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—AKT1—head and neck cancer	9.77e-06	8.92e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—AKT1—head and neck cancer	9.74e-06	8.89e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—head and neck cancer	9.71e-06	8.86e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—head and neck cancer	9.7e-06	8.85e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—AKT1—head and neck cancer	9.65e-06	8.8e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—AKT1—head and neck cancer	9.62e-06	8.78e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—TYMS—head and neck cancer	9.6e-06	8.77e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.58e-06	8.74e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GSTM1—head and neck cancer	9.49e-06	8.67e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MAPK3—head and neck cancer	9.48e-06	8.66e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MAPK1—head and neck cancer	9.48e-06	8.65e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EGFR—head and neck cancer	9.47e-06	8.65e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—PIK3CA—head and neck cancer	9.44e-06	8.61e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	9.43e-06	8.6e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EGFR—head and neck cancer	9.43e-06	8.6e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—head and neck cancer	9.28e-06	8.47e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—head and neck cancer	9.24e-06	8.44e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—STAT3—head and neck cancer	9.15e-06	8.35e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—head and neck cancer	9.13e-06	8.33e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—PIK3CA—head and neck cancer	9.12e-06	8.32e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	9.1e-06	8.3e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—GPX1—head and neck cancer	9.09e-06	8.3e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—head and neck cancer	9.08e-06	8.28e-05	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—AKT1—head and neck cancer	9.07e-06	8.28e-05	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—AKT1—head and neck cancer	9.06e-06	8.27e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—head and neck cancer	9.05e-06	8.26e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MAPK1—head and neck cancer	9.02e-06	8.24e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EGFR—head and neck cancer	9.02e-06	8.24e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—head and neck cancer	9.02e-06	8.23e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—STAT3—head and neck cancer	9.01e-06	8.22e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	9e-06	8.21e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—STAT3—head and neck cancer	8.99e-06	8.2e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—STAT3—head and neck cancer	8.96e-06	8.18e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—head and neck cancer	8.93e-06	8.15e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—STAT3—head and neck cancer	8.93e-06	8.15e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—head and neck cancer	8.91e-06	8.13e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTGS2—head and neck cancer	8.9e-06	8.12e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—STAT3—head and neck cancer	8.84e-06	8.07e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—STAT3—head and neck cancer	8.82e-06	8.05e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK3—head and neck cancer	8.74e-06	7.98e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—head and neck cancer	8.73e-06	7.97e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTGS2—head and neck cancer	8.69e-06	7.93e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	8.6e-06	7.85e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK3—head and neck cancer	8.59e-06	7.84e-05	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—AKT1—head and neck cancer	8.56e-06	7.81e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK3—head and neck cancer	8.56e-06	7.81e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK3—head and neck cancer	8.53e-06	7.79e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK3—head and neck cancer	8.45e-06	7.71e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK3—head and neck cancer	8.42e-06	7.69e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—PIK3CA—head and neck cancer	8.42e-06	7.69e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MAPK1—head and neck cancer	8.32e-06	7.59e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EGFR—head and neck cancer	8.32e-06	7.59e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—PIK3CA—head and neck cancer	8.22e-06	7.51e-05	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—AKT1—head and neck cancer	8.2e-06	7.48e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	8.19e-06	7.47e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTGS2—head and neck cancer	8.19e-06	7.47e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EGFR—head and neck cancer	8.19e-06	7.47e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	8.18e-06	7.47e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MAPK1—head and neck cancer	8.17e-06	7.46e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EGFR—head and neck cancer	8.17e-06	7.45e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MAPK1—head and neck cancer	8.14e-06	7.43e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EGFR—head and neck cancer	8.14e-06	7.43e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MAPK1—head and neck cancer	8.12e-06	7.41e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EGFR—head and neck cancer	8.12e-06	7.41e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MAPK1—head and neck cancer	8.04e-06	7.34e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EGFR—head and neck cancer	8.04e-06	7.34e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MAPK1—head and neck cancer	8.02e-06	7.32e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EGFR—head and neck cancer	8.01e-06	7.32e-05	CbGpPWpGaD
Imipramine—CYP3A7—Metabolism—AKT1—head and neck cancer	8e-06	7.31e-05	CbGpPWpGaD
Imipramine—SLC22A2—Metabolism—AKT1—head and neck cancer	7.99e-06	7.29e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—head and neck cancer	7.96e-06	7.26e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—head and neck cancer	7.91e-06	7.22e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—PIK3CA—head and neck cancer	7.83e-06	7.15e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PTEN—head and neck cancer	7.76e-06	7.08e-05	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—AKT1—head and neck cancer	7.71e-06	7.04e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—head and neck cancer	7.61e-06	6.94e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PTEN—head and neck cancer	7.58e-06	6.92e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—head and neck cancer	7.58e-06	6.91e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—head and neck cancer	7.57e-06	6.91e-05	CbGpPWpGaD
Imipramine—SLC22A1—Metabolism—AKT1—head and neck cancer	7.45e-06	6.8e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—PIK3CA—head and neck cancer	7.25e-06	6.61e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—head and neck cancer	7.25e-06	6.61e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—PIK3CA—head and neck cancer	7.22e-06	6.59e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PTEN—head and neck cancer	7.14e-06	6.52e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	7.1e-06	6.48e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—PIK3CA—head and neck cancer	7.1e-06	6.48e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—PIK3CA—head and neck cancer	7.09e-06	6.47e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—PIK3CA—head and neck cancer	7.07e-06	6.45e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—PIK3CA—head and neck cancer	7.04e-06	6.43e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—head and neck cancer	6.98e-06	6.38e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—PIK3CA—head and neck cancer	6.98e-06	6.37e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—PIK3CA—head and neck cancer	6.96e-06	6.35e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTGS2—head and neck cancer	6.94e-06	6.33e-05	CbGpPWpGaD
Imipramine—CHRM3—Metabolism—AKT1—head and neck cancer	6.88e-06	6.28e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—head and neck cancer	6.87e-06	6.27e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—head and neck cancer	6.86e-06	6.26e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—head and neck cancer	6.84e-06	6.24e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—head and neck cancer	6.81e-06	6.22e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—head and neck cancer	6.75e-06	6.16e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—head and neck cancer	6.73e-06	6.14e-05	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—AKT1—head and neck cancer	6.72e-06	6.13e-05	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—AKT1—head and neck cancer	6.68e-06	6.1e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—head and neck cancer	6.68e-06	6.1e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—head and neck cancer	6.57e-06	6e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—head and neck cancer	6.56e-06	5.99e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—head and neck cancer	6.54e-06	5.97e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—head and neck cancer	6.52e-06	5.95e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—head and neck cancer	6.45e-06	5.89e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—head and neck cancer	6.44e-06	5.87e-05	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—AKT1—head and neck cancer	6.4e-06	5.84e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PTEN—head and neck cancer	6.05e-06	5.52e-05	CbGpPWpGaD
Imipramine—CYP2B6—Metabolism—AKT1—head and neck cancer	5.92e-06	5.4e-05	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—AKT1—head and neck cancer	5.9e-06	5.38e-05	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—AKT1—head and neck cancer	5.8e-06	5.3e-05	CbGpPWpGaD
Imipramine—CYP2E1—Metabolism—AKT1—head and neck cancer	5.8e-06	5.29e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—AKT1—head and neck cancer	5.79e-06	5.29e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—AKT1—head and neck cancer	5.77e-06	5.27e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—AKT1—head and neck cancer	5.75e-06	5.25e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—AKT1—head and neck cancer	5.7e-06	5.2e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—AKT1—head and neck cancer	5.68e-06	5.19e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—PIK3CA—head and neck cancer	5.48e-06	5e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTGS2—head and neck cancer	5.35e-06	4.89e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—PIK3CA—head and neck cancer	5.34e-06	4.88e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	5.04e-06	4.6e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PTEN—head and neck cancer	4.67e-06	4.26e-05	CbGpPWpGaD
Imipramine—CYP2C19—Metabolism—AKT1—head and neck cancer	4.47e-06	4.08e-05	CbGpPWpGaD
Imipramine—ABCB1—Metabolism—AKT1—head and neck cancer	4.37e-06	3.99e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—PIK3CA—head and neck cancer	4.27e-06	3.89e-05	CbGpPWpGaD
Imipramine—CYP2D6—Metabolism—AKT1—head and neck cancer	4.11e-06	3.76e-05	CbGpPWpGaD
Imipramine—CYP1A2—Metabolism—AKT1—head and neck cancer	3.49e-06	3.18e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	3.29e-06	3.01e-05	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—AKT1—head and neck cancer	2.69e-06	2.46e-05	CbGpPWpGaD
